Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
Versiti Blood Research Institute posted on LinkedIn:
”New research from VBRI investigator Phillip Doerfler uncovers new insights into sickle cell disease protection: uniform expression of fetal hemoglobin matters as much as its quantity.
Doerfler and colleagues from St. Jude Children’s Research Hospital, Christian Medical College Vellore, and University of Minnesota used single-cell RNA sequencing to examine blood cells from patients with two genetic variations that increase fetal hemoglobin, a protein that prevents sickling.
Patients whose cells expressed fetal hemoglobin consistently had no sickle cell symptoms. Patients with dramatic variation (some cells carrying high levels, others with very little) suffered pain crises and acute chest syndrome despite similar average hemoglobin percentages.
The difference is immense. Traditional tests measure what percentage of cells express fetal hemoglobin, but cannot detect how much each cell produces. How can we know whether a patient is protected?
The discovery offers crucial guidance for gene therapy approaches that reactivate fetal hemoglobin. Consistency of expression across the cell population may predict clinical benefit better than average levels alone.
Read the article in Blood Journals Portfolio’s Blood.
Advances here.”
Title: Single-cell transcriptomics reveals heterocellular g-globin gene expression in Agdb-thalassemia
Authors: Phillip A Doerfler, Yichao Li, Yu Yao, Ruopeng Feng, Thiyagaraj Mayuranathan, Jingjing Zhang, Emilia Kooienga, David Cullins, Rohith Jesudas, Dillon C Williams, Jane S Hankins, Yong Cheng, David K Wood, Mitchell J. Weiss
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits